CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) — Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hyperplasia (“BPH”) asset, ENTADFI®.
“Blue Water’s recent growth is highlighted by our acquisition of ENTADFI®, as well as our subsequent rebranding initiative and name change to reflect our transition into a commercial-stage biotechnology company,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. “We believe this product has the potential to be transformative for men suffering from BPH, and we are confident that our experienced management team will be the driving force behind ENTADFI®’s anticipated success. We are also excited to bring in an approved asset to support the operations for our preclinical vaccine programs, including our Streptococcus pneumoniae vaccine candidate that is progressing towards clinical trials in the near term.”
Q1 2023 and Recent Corporate Developments
Q1 2023 and Recent Vaccine Candidate Developments
Q1 2023 Financial Highlights
BLUE WATER BIOTECH, INC.
Condensed Balance Sheets
March 31, 2023 |
December 31, 2022 |
|||||||
ASSETS | (Unaudited) | |||||||
Current assets | ||||||||
Cash | $ | 20,255,803 | $ | 25,752,659 | ||||
Restricted cash | 1,000,000 | — | ||||||
Prepaid expenses and other current assets | 780,173 | 469,232 | ||||||
Deferred offering costs | 366,113 | — | ||||||
Receivable from related parties | 70,302 | 35,850 | ||||||
Total current assets | 22,472,391 | 26,257,741 | ||||||
Prepaid expenses, long-term | 15,500 | 38,617 | ||||||
Property and equipment, net | 14,210 | 14,089 | ||||||
Total assets | $ | 22,502,101 | $ | 26,310,447 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 1,503,262 | $ | 1,499,296 | ||||
Accrued expenses | 1,292,951 | 2,409,128 | ||||||
Contingent warrant liability | 12,406 | 14,021 | ||||||
Total current liabilities | 2,808,619 | 3,922,445 | ||||||
Total liabilities | 2,808,619 | 3,922,445 | ||||||
Commitments and Contingencies | ||||||||
Stockholders’ equity | ||||||||
Preferred stock, $0.00001 par value, 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; 0 shares issued and outstanding at March 31, 2023 and December 31, 2022 | — | — | ||||||
Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2023 and December 31, 2022; 16,371,597 and 15,724,957 shares issued at March 31, 2023 and December 31, 2022, respectively; 15,879,230 and 15,265,228 shares outstanding at March 31, 2023 and December 31, 2022, respectively | 164 | 157 | ||||||
Additional paid-in-capital | 42,516,726 | 42,331,155 | ||||||
Treasury stock, at cost; 492,367 and 459,729 shares of common stock at March 31, 2023 and December 31, 2022, respectively | (600,264 | ) | (566,810 | ) | ||||
Accumulated deficit | (22,223,144 | ) | (19,376,500 | ) | ||||
Total stockholders’ equity | 19,693,482 | 22,388,002 | ||||||
Total liabilities and stockholders’ equity | $ | 22,502,101 | $ | 26,310,447 |
BLUE WATER BIOTECH, INC.
Condensed Statements of Operations
(Unaudited)
Three Months Ended March 31, 2023 |
Three Months Ended March 31, 2022 |
||||||||
Operating expenses | |||||||||
General and administrative | $ | 1,766,022 | $ | 1,615,569 | |||||
Research and development | 1,082,237 | 455,092 | |||||||
Total operating expenses | 2,848,259 | 2,070,661 | |||||||
Loss from operations | (2,848,259 | ) | (2,070,661 | ) | |||||
Other income | |||||||||
Change in fair value of contingent warrant liability | (1,615 | ) | — | ||||||
Total other income | (1,615 | ) | — | ||||||
Net loss | $ | (2,846,644 | ) | $ | (2,070,661 | ) | |||
Cumulative preferred stock dividends | — | 96,359 | |||||||
Net loss applicable to common stockholders | (2,846,644 | ) | (2,167,020 | ) | |||||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.18 | ) | $ | (0.34 | ) | |||
Weighted average number of common shares outstanding, basic and diluted | 15,910,415 | 6,339,435 | |||||||
About ENTADFI®
ENTADFI® is an oral, once daily treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, offering a more effective treatment option compared to other available therapies. Clinical trials have shown that ENTADFI® is more effective in treating BPH symptoms, including urinary frequency, urgency, weak stream, and difficulty initiating or maintaining urination, compared to finasteride monotherapy. Additionally, ENTADFI® has demonstrated a favorable safety profile, with fewer adverse sexual side effects compared to finasteride. ENTADFI® reduces potential for adverse sexual side effects, making it a preferred choice for men seeking relief from BPH symptoms without compromising their sexual health. ENTADFI® has received FDA approval for the indication of initiating treatment of the signs and symptoms of BPH in men with an enlarged prostate for up to 26 weeks. More information about BPH and full ENTADFI® prescribing information can be found on the product website at https://entadfipatient.com/.
About Blue Water Biotech
Blue Water Biotech, Inc. is a biological and pharmaceutical technology company focused on developing and providing transformational therapies to address significant health challenges globally. Headquartered in Cincinnati, OH, the Company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children’s Hospital Medical Center, St. Jude Children’s Hospital, and The University of Texas Health Science Center at San Antonio. Blue Water is developing a Streptococcus pneumoniae vaccine candidate, designed to specifically prevent highly infectious middle ear infections, known as acute otitis media (AOM), in children, and prevention of pneumonia in the elderly. The Company is also developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, among others. Additionally, the Company is developing a Chlamydia vaccine candidate with UT Health Science Center San Antonio to prevent infection and reduce the need for antibiotic treatment associated with contracting Chlamydia disease. Outside of its vaccine franchise, Blue Water owns ENTADFI®, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. This combination allows men to receive treatment for their symptoms of BPH without the negative sexual side effects typically seen in patients on finasteride alone. For more information about Blue Water, visit www.bwbioinc.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Blue Water’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to Blue Water’s ability to realize the benefits of its acquisition of ENTADFI®, risks related to BWV’s ability to expand its business scope and its ability to commercialize ENTADFI®, risks related to the development of Blue Water’s vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products. Blue Water does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Blue Water’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 9, 2023 and periodic reports filed with the SEC on or after the date thereof. All of Blue Water’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Media Contact Information:
Blue Water Media Relations
Telephone: (646) 942-5591
Email: Nic.Johnson@russopartnersllc.com
Investor Contact Information:
Blue Water Investor Relations
Email: investors@bwbioinc.com
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
NEW YORK, Nov. 22, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape -…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…
The new app allows users to browse services, book IV therapy, manage appointments, purchase packages,…
PHILADELPHIA, Nov. 22, 2024 /PRNewswire/ -- Independence Blue Cross (IBX) is implementing the Epic Payer Platform…